Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

Research Down Syndrome (RDS), a nonprofit foundation that is among the leading sources for funding of Down syndrome related cognitive research, is entering the second year of its national running program, Race for the Extraordinary, to help increase public awareness and funding for Down syndrome research. The mission of ...

Into Action Treatment, located in beautiful South Florida, has entered the year 2012 with a new and exceptional rehab program. Offering the Substance Abuse population several levels of treatment services, Into Action Treatment provides cutting edge clinical therapy models while adhering to basic 12 step philosophies.

Cambridge, MA, and Columbia, MO. January 17, 2012 BGI, the world's largest genomics organization, announced today that it has been selected by the National Center for Soybean Biotechnology at the University of Missouri to re-sequence 1,008 soybean germplasm lines, commencing with an initial contract in 2012 to re-sequence the first ...

The iMPak Health Journal for Pain empowers patients to easily record their pain levels before and after their prescribed medication regimen, providing physicians with readily available, useful, patient information.

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine.

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash ...

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that it has entered into a $5 million securities purchase agreement with Socius CG II, Ltd. ("Socius"), a Bermuda-based subsidiary of Socius Capital Group, LLC.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

A US federal judge is set to hear arguments Tuesday about the government's decision to deny over-the-counter access of emergency contraception to women of all ages, as part of a decade-long legal battle.

Quality Systems, Inc., a leading provider of healthcare information systems and connectivity solutions, today announced that it has entered into an agreement to acquire ViaTrack Systems, a developer and provider of information technologies that enhance electronic data interchange (EDI) offerings.

Statens Serum Institut and Aeras today announce the initiation of the first Phase I clinical trial of a new candidate TB vaccine designed to protect people latently infected with TB from developing active TB disease. The trial is being conducted by the South African Tuberculosis Vaccine Initiative (SATVI) at its ...